Placon Therapeutics, Inc.

Aveo Pharmaceuticals, Inc.

Tarveda Therapeutics, Inc.

Kerry Whalen

Mark T Bilodeau

Richard Wooster

Benoît Moreau

Kristan Meetze

Rossitza Gueorguieva Alargova

Ting Chen

Jeno Gyuris

William M Winston, Jr

Lyne Breault

Solly Weiler

Rajesh R Shinde

May Han

Lorena Lerner

Sylvie Vincent

Steve Bottega

Qing Liu

Adam H Brockman

James Gifford

Jinwei Jiang

Andrea Boudrow

J Michael Ramstack

Sudhakar Kadiyala

Brian H White

Patrick Lim Soo

Beata Sweryda-Krawiec

Patrick Rosaire Bazinet

Charles-André Lemelin

Samantha Perino

Danielle N Rockwood

Leila Alland

Mary Simcox

Sukhjeet Singh

Tsun P Au Yeung

Linda M Custer

Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.

HSP90-targeting conjugates and formulations thereof

Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.

SSTR-targeted conjugates and particles and formulations thereof

The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one reacting group for reacting with a functional group on a protein.

Platinum compounds, compositions, and uses thereof

The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one reacting group for reacting with a functional group on a protein, engineered protein, antibody, antibody fragment, peptide, agonist, antagonist, aptamer or ligand which may be capable of recognizing a selected target cell population, and/or derivatives/analogs/mimics thereof.

Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d'Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.

Anti-ron antibodies

Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d' Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.

Anti-RON antibodies

Growing community of inventors

Waltham, MA, United States of America

Kerry Whalen